

**GSK Limited**

**(Registered number: 12215835 )**

**Directors' report and financial statements**

**for the period from 19 September 2019 (date of incorporation) to 31 December 2020**



**Registered office address:**

Gsk House,  
980 Great West Road,  
Brentford,  
United Kingdom, TW8 9GS  
England

**GSK Limited**  
**(Registered number: 12215835 )**

**Directors' report and financial statements**

**for the period from 19 September 2019 to 31 December 2020**

<b>Contents</b>	<b>Pages</b>
Directors' report	1-3
Statement of comprehensive income	4
Balance sheet	5
Notes to the financial statements	6-9

**GSK Limited**  
**(Registered number: 12215835 )**

## **Directors' report for the period from 19 September 2019 to 31 December 2020**

The Directors present their report on GSK Limited (the 'Company') and the financial statements of the Company for the period from 19 September 2019 to 31 December 2020 ('financial period').

### **Principal activities and future developments**

The Company is a member of the GlaxoSmithKline Group (the "Group"). The Company is a private company limited by shares and is incorporated and domiciled in the UK (England). The address of the registered office is 980 Great West Road, Brentford, Middlesex, TW8 9GS.

The Company did not trade during the period. The Directors do not envisage any change to the nature of the business in the foreseeable future.

### **Review of business**

The Company made no profit or loss during the period. Since incorporation the company did not trade and so the Directors are of the opinion that the Company will remain dormant for the foreseeable future. There was no transfer to or from reserves for the period.

### **Directors**

The Directors of the Company who were in office during the period and up to the date of signing the financial statements were as follows:

Victoria Anne Whyte	(Appointed on 19 September 2019)
The Wellcome Foundation Limited	(Appointed on 19 September 2019)
Edinburgh Pharmaceutical Industries Limited	(Appointed on 6 May 2021)

No Director had, during the period or at the end of the period, any material interest in any contract of significance to the Company's business with the exception of the Corporate Directors, where such an interest may arise in the ordinary course of business. A Corporate Director is a legal entity of the Group as opposed to a natural person (an individual) Director.

### **Directors' indemnity**

Each of the Directors benefits from an indemnity given by the Company under its articles of association. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of their duties.

In addition, each of the Directors who is an individual benefits from an indemnity given by another Group company, GlaxoSmithKline Services Unlimited. This indemnity is in respect of liabilities arising out of third party proceedings to which the Director is a party by virtue of their engagement in the business of the Company.

### **Statement of Directors' responsibilities**

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 101 "Reduced Disclosure Framework", and applicable law). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

**GSK Limited****(Registered number: 12215835 )****Directors' report for the period from 19 September 2019 to 31 December 2020 (continued)****Statement of Directors' responsibilities (continued)**

In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK accounting standards, comprising FRS 101, have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. The Directors are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Going concern**

Having assessed the principal risks and other matters, including the potential impact of the COVID-19 pandemic, the Directors are of the opinion that the current level of activity remains sustainable. In relation to the challenges that arise from the COVID-19 pandemic, the considerations have included Company's activities. The Directors have taken into account that as part of the Group, the Company has the ability to request support from the Group where necessary and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.

**Impact of Brexit**

The UK left the EU on 31 January 2020 and the Brexit transition period ended on 31 December 2020 with a Trade and Cooperation Agreement ('a deal') in place between the UK and EU. The Group's overriding priority in preparing for the UK's exit from the EU has been to maintain continuity of supply of our medicines and vaccines to people in the UK and EU. The Group's post-Brexit operating model has been implemented, and we continue to work closely with Governments in both the UK and EU, as well as our third parties, on the effective implementation of the deal and to ensure that our sector continues to thrive both in the UK and EU. Over the longer term, we continue to believe that Brexit will not have a material impact on our business.

**Risks associated with the coronavirus outbreak**

The potential impact of the COVID-19 pandemic on the Company's performance and all its principal risks have been assessed with mitigation plans put in place. The Company continues to monitor the situation closely, as this continues to be a dynamic and an uncertain situation, with the ultimate severity, duration and impact unknown at this point including potential impacts on its activity. The situation could change at any time and there can be no assurance that the COVID-19 pandemic will not have a material adverse impact on the future results of the Company.

**GSK Limited**  
**(Registered number: 12215835 )**

**Directors' report for the period from 19 September 2019 to 31 December 2020 (continued)**

**Audit and small company exemption**

The Company has taken advantage of the audit exemption set out within section 479A of the Companies Act 2006 for the year ended 31 December 2020.

This report has been prepared taking advantage of the small companies exemption in accordance with section 415A of the Companies Act 2006.

By order of the Board



J Sadler  
Authorised Signatory  
For and on behalf of The Wellcome Foundation Limited-Corporate Director  
01 July 2021

**GSK Limited**  
**(Registered number: 12215835 )**

**Statement of comprehensive income**  
**for the period from 19 September 2019 to 31 December 2020**

	For the period from 19 September 2019 to 31 December 2020
Notes	£
Turnover	
Cost of sales	
Gross profit	-
Other operating income/(expense)	-
<b>Profit before taxation</b>	-
Taxation	-
<b>Profit after taxation</b>	-

The results disclosed above relate entirely to continuing operations.

The Company has no other comprehensive income during the current period and therefore no separate statement to present other comprehensive income has been prepared.

**GSK Limited**  
**(Registered number: 12215835 )**

**Balance sheet**  
**as at 31 December 2020**

	Notes	2020 £
<b>Current assets</b>		
Other receivables	5	1
<b>Net current assets</b>		<b>1</b>
<b>Net assets</b>		<b>1</b>
<b>Equity</b>		
Share capital	6	1
<b>Shareholder's equity</b>		<b>1</b>

For the period ending 31 December 2020, the Company was entitled to exemption for audit under section 479A of the Companies Act 2006 relating to subsidiary companies.

**Directors' responsibilities**

- The members have not required the Company to obtain an audit in accordance with section 476 of the Companies Act 2006; and
- The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 4 to 9 were approved by the Board of Directors on 1 July 2021 and signed on its behalf by:



J Sadler  
Authorised Signatory  
For and on behalf of The Wellcome Foundation Limited-Corporate Director

**GSK Limited**  
**(Registered number: 12215835 )**

**Notes to the financial statements for the period from 19 September 2019 to 31 December 2020**

**1 Presentation of the financial statements**

**General information**

The Company is a private company limited by shares, and is incorporated and domiciled in the UK (England). The address of the registered office is 980 Great West Road, Brentford, Middlesex, TW8 9GS.

**2 Summary of significant accounting policies**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied, unless otherwise stated.

**(a) Basis of preparation**

The financial statements have been prepared in accordance with Financial Reporting Standard 100 Application of Financial Reporting Requirements ("FRS 100") and Financial Reporting Standard 101 Reduced Disclosure Framework ("FRS 101").

These financial statements have been prepared on the going concern basis under the historical cost convention, and in accordance with the Companies Act 2006.

The financial statements are presented in Pounds Sterling.

**Going concern**

Having assessed the principal risks and other matters, including the potential impact of the COVID-19 pandemic, the Directors are of the opinion that the current level of activity remains sustainable. In relation to the challenges that arise from the COVID-19 pandemic, the considerations have included Company's activities. The Directors have taken into account that as part of the Group, the Company has the ability to request support from the Group where necessary and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.

**Disclosure exemptions adopted**

In preparing these financial statements the Company has taken advantage of all disclosure exemptions conferred by FRS 101 to requirements set by the International Financial Reporting Standards (IFRS). Therefore these financial statements do not include:

- Paragraphs 45(b) and 46 to 52 of IFRS 2, 'Share-based payments' (details of the number and weighted-average exercise prices of share options, and how the fair value of goods or services received was determined);
- The requirements of paragraphs 62, B64(d), B64(e), B64(g), B64(h), B64(j) to B64(m), B64(n)(ii), B64(o)(ii), B64(p), B64(q)(ii), B66 and B67 of IFRS 3, 'Business Combinations';
- The requirements of paragraph 33(c) of IFRS 5, 'Non-current Assets Held for Sale and Discontinued operations';
- IFRS 7, 'Financial instruments: disclosures';
- The requirements of the second sentence of paragraph 110 and paragraphs 113(a), 114, 115, 118, 119(a) to (c), 120 to 127 and 129 of IFRS 15, 'Revenue from Contracts with Customers';
- Paragraphs 91 to 99 of IFRS 13, 'Fair value measurement' (disclosure of valuation techniques and inputs used for fair value measurement of assets and liabilities);



**GSK Limited**  
**(Registered number: 12215835 )**

**Notes to the financial statements for the period from 19 September 2019 to 31 December 2020**

**2 Summary of significant accounting policies (continued)**

**(a) Basis of preparation (continued)**

**Disclosure exemptions adopted (continued)**

- Paragraph 38 of IAS 1, 'Presentation of financial statements' comparative information requirements in respect of:
  - (i) paragraph 79(a) (iv) of IAS 1;
  - (ii) paragraph 73(e) of IAS 16, 'Property, plant and equipment';
  - (iii) paragraph 118(e) of IAS 38, 'Intangible assets' (reconciliations between the carrying amount at the beginning and end of the period);
  - (iv) paragraph 76 and 79(d) of IAS 40, 'Investment property'; and
  - (v) paragraph 50 of IAS 41, 'Agriculture'.
- The following paragraphs of IAS 1, 'Presentation of financial statements':
  - 10(d), (statement of cash flows),
  - 10(f), (a balance sheet as at the beginning of the preceding period when an entity applies an accounting policy retrospectively or make a retrospective restatement of items in its financial statements, or when it reclassifies items in its financial statements),
  - 16 (statement of compliance with all IFRS),
  - 38A (requirements for minimum of two primary statements, including cash flow statements),
  - 38B-D (additional comparative information),
  - 40A-D (requirements for a third balance sheet),
  - 111 (cash flow statement information), and
  - 134 - 136 (capital management disclosures).
- IAS 7, 'Statement of cash flows';
- The requirements of paragraph 52, the second sentence of paragraph 89, and paragraphs 90, 91 and 93 of IFRS 16, 'Leases';
- The requirements of paragraph 58 of IFRS 16, provided that the disclosure of details of indebtedness required by paragraph 61(1) of Schedule 1 to the Regulations is presented separately for lease liabilities and other liabilities, and in total;
- Paragraph 30 and 31 of IAS 8 'Accounting policies, changes in accounting estimates and errors' (requirement for the disclosure of information when an entity has not applied a new IFRS that has been issued but is not yet effective);
- Paragraph 17 and 18A of IAS 24, 'Related party disclosures' (key management compensation);
- The requirements in IAS 24, 'Related party disclosures' to disclose related party transactions entered into between two or more wholly owned members of a company; and
- The requirements of paragraphs 130(f)(ii), 130(f)(iii), 134(d) to 134(f) and 135(c) to 135(e) of IAS 36, 'Impairment of Assets'.

The financial statements of GlaxoSmithKline plc can be obtained as described in note 2(b).

The preparation of financial statements in conformity with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies.

**GSK Limited**  
**(Registered number: 12215835 )**

**Notes to the financial statements for the period from 19 September 2019 to 31 December 2020**

**2 Summary of significant accounting policies (continued)**

**(b) Ultimate and immediate parent undertaking**

The Company is a wholly owned subsidiary of the ultimate parent company. GlaxoSmithKline plc, a company incorporated in United Kingdom (England), is the Company's ultimate parent undertaking and controlling party. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated financial statements can be obtained from the Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS. The immediate parent undertaking is Glaxo Group Limited. These financial statements are separate financial statements.

**(c) Other receivables**

For other receivables, the general approach is used where the entity recognises the losses that are expected to result from all possible default events over the expected life of the receivable, when there has been a significant increase in credit risk since initial recognition. However, if the credit risk on the receivable has not increased significantly since initial recognition, the entity measures the expected loss allowance based on losses that are expected to result from default events that are possible within 12 months after the reporting date. When a trade and other receivable is determined to be uncollectable it is written off, firstly against any expected credit loss allowance available and then to the statement of comprehensive income.

Subsequent recoveries of amounts previously provided for are credited to the statement of comprehensive income.

**(d) Share capital**

Ordinary shares are classified as equity.

**3 Critical accounting judgements and key sources of estimation uncertainty**

In preparing the financial statements, the Directors are required to make estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates.

The Directors do not consider that there are any critical accounting judgements that have been made in the process of applying the Company's accounting policies and that have had a significant effect on the amounts recognised in the financial statements. There have been no significant estimates or assumptions which are likely to cause a material adjustment to the carrying amount of assets and liabilities within the next financial period.

**4 Employees**

The Company has no employees as all employees are employed by other Group companies.

**5 Other receivables**

	<b>2020</b>
	<b>£</b>
<b>Amounts due within one year</b>	
Amounts owed by Group undertakings	<b>1</b>

The amounts owed by group undertakings are unsecured, interest free and are repayable on demand.

**GSK Limited**  
**(Registered number: 12215835 )**

**Notes to the financial statements for the period from 19 September 2019 to 31 December 2020**

**6 Share capital**

	<b>2020</b>	<b>2020</b>
	<b>Number of</b>	
	<b>shares</b>	<b>£</b>
<b>Issued and fully paid</b>		
Ordinary Shares of £1 each	<b>1</b>	<b>1</b>
	<b>1</b>	<b>1</b>

**7 Directors' remuneration**

Corporate Directors received no remuneration during the period, either as executives of the Group or in respect of their service to the Company.